[{"orgOrder":0,"company":"SciTech Development","sponsor":"Storm Lake Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Fenretinide","moa":"RAR","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SciTech Development \/ Storm Lake Capital","highestDevelopmentStatusID":"6","companyTruncated":"SciTech Development \/ Storm Lake Capital"},{"orgOrder":0,"company":"SciTech Development","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fenretinide","moa":"RAR","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SciTech Development","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SciTech Development \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SciTech Development \/ Inapplicable"},{"orgOrder":0,"company":"SciTech Development","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fenretinide","moa":"RAR","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SciTech Development \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SciTech Development \/ Inapplicable"},{"orgOrder":0,"company":"SciTech Development","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fenretinide","moa":"RAR","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SciTech Development \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SciTech Development \/ Inapplicable"},{"orgOrder":0,"company":"SciTech Development","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Fenretinide","moa":"RAR","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SciTech Development \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SciTech Development \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by SciTech Development

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : ST-001 (nanofenretinide) works by inhibiting the growth of cancer cell, currently it is being investiated for T-cell non-Hodgkin lymphoma and for small cell lung cancer.

                          Product Name : ST-001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 13, 2025

                          Lead Product(s) : Fenretinide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : ST-001 (fenretinide), is currently undergoing trials in IV infusion form for treating patients with T-cell non-Hodgkin's lymphoma, including Peripheral T-cell Lymphoma and Sezary Syndrome.

                          Product Name : ST-001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 03, 2024

                          Lead Product(s) : Fenretinide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : The financing will be used to advance the company's Phase 1b clinical trials of ST-001 (nanofenretinide) for T-cell non-Hodgkin lymphoma and subsequent clinical trials for small cell lung cancer.

                          Product Name : ST-001

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 06, 2024

                          Lead Product(s) : Fenretinide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Storm Lake Capital

                          Deal Size : $3.2 million

                          Deal Type : Financing

                          blank

                          04

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : SciTech's primary drug candidate, ST-001 (fenretinide), is currently undergoing Phase I clinical trials in IV infusion form for treating patients with T-cell non-Hodgkin's lymphoma, including Peripheral T-cell Lymphoma and Sezary Syndrome.

                          Product Name : ST-001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 20, 2023

                          Lead Product(s) : Fenretinide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Fenretinide has demonstrated preclinical in-vitro antiviral activity against a number of viruses including MERs, Dengue, Zika, West Nile, HIV, and HCV.

                          Product Name : ST-001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 16, 2020

                          Lead Product(s) : Fenretinide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank